Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Medicure (MCUJF) Cash & Equivalents (2016 - 2025)

Medicure has reported Cash & Equivalents over the past 17 years, most recently at $5.2 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents changed 0.17% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, changed 0.17%, while the annual FY2025 figure was $5.2 million, 0.17% changed from the prior year.
  • Cash & Equivalents for Q4 2025 was $5.2 million at Medicure, down from $5.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $5.2 million in Q3 2025 and troughed at $2.1 million in Q1 2021.
  • A 5-year average of $3.6 million and a median of $3.6 million in 2023 define the central range for Cash & Equivalents.
  • Biggest five-year swings in Cash & Equivalents: plummeted 77.82% in 2021 and later skyrocketed 44.29% in 2024.
  • Year by year, Cash & Equivalents stood at $2.2 million in 2021, then grew by 26.3% to $2.7 million in 2022, then skyrocketed by 31.1% to $3.6 million in 2023, then skyrocketed by 44.29% to $5.1 million in 2024, then increased by 0.17% to $5.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for MCUJF at $5.2 million in Q4 2025, $5.2 million in Q3 2025, and $3.4 million in Q2 2025.